Clarivate PLC

CLVT is in an early Stage 1 consolidation with rising 9/21 EMAs and mean-reversion eligibility, supporting a tactical bullish stance. Neutral OB/OS and absence of active bearish patterns suggest price asymmetry favors upside. Price is holding above the short EMAs within a tight range. Execution should be deferred—stalking for pullbacks into the EMAs or the lower end of the consolidation zone.

• ↑Earnings yield of 1.87% and book-to-price of 3.16x indicate undervaluation.
• ↑Guidance calls for 2–3% organic ACV growth and $400M FCF by 2026.
• ↓Q1 net loss of $40M underscores ongoing unprofitability.